{"protocolSection": {"identificationModule": {"nctId": "NCT02738879", "orgStudyIdInfo": {"id": "0431-845"}, "secondaryIdInfos": [{"id": "2015-004990-34", "type": "EUDRACT_NUMBER"}, {"id": "MK-0431-845", "type": "OTHER", "domain": "Merck Protocol Number"}], "organization": {"fullName": "Merck Sharp & Dohme LLC", "class": "INDUSTRY"}, "briefTitle": "Randomized Sitagliptin Withdrawal Study (MK-0431-845)", "officialTitle": "A Phase III, Multicenter, Randomized, Double-Blind, Placebo-Controlled Clinical Trial to Study the Efficacy and Safety of the Continuation of Sitagliptin Compared With the Withdrawal of Sitagliptin During Initiation and Titration of Insulin Glargine (LANTUS\u00ae) in Subjects With Type 2 Diabetes Mellitus"}, "statusModule": {"statusVerifiedDate": "2019-02", "overallStatus": "COMPLETED", "expandedAccessInfo": {"hasExpandedAccess": false}, "startDateStruct": {"date": "2016-05-09", "type": "ACTUAL"}, "primaryCompletionDateStruct": {"date": "2018-01-22", "type": "ACTUAL"}, "completionDateStruct": {"date": "2018-01-30", "type": "ACTUAL"}, "studyFirstSubmitDate": "2016-04-11", "studyFirstSubmitQcDate": "2016-04-11", "studyFirstPostDateStruct": {"date": "2016-04-14", "type": "ESTIMATED"}, "resultsFirstSubmitDate": "2019-01-18", "resultsFirstSubmitQcDate": "2019-02-22", "resultsFirstPostDateStruct": {"date": "2019-02-25", "type": "ACTUAL"}, "lastUpdateSubmitDate": "2019-02-22", "lastUpdatePostDateStruct": {"date": "2019-02-25", "type": "ACTUAL"}}, "sponsorCollaboratorsModule": {"responsibleParty": {"type": "SPONSOR"}, "leadSponsor": {"name": "Merck Sharp & Dohme LLC", "class": "INDUSTRY"}}, "oversightModule": {"oversightHasDmc": false}, "descriptionModule": {"briefSummary": "This is a trial of continuing sitagliptin versus withdrawing sitagliptin in participants with Type 2 diabetes mellitus (T2DM) and inadequate glycemic control who initiate and titrate insulin glargine (LANTUS\u00ae) based on a treat-to-target algorithm to achieve fasting glucose levels of 72-100 mg/dL (4-5.6 mmol/L). A primary hypothesis of this trial is that after 30 weeks, continuing sitagliptin results in a greater reduction of hemoglobin A1C (A1C) relative to withdrawing sitagliptin."}, "conditionsModule": {"conditions": ["Type 2 Diabetes Mellitus"]}, "designModule": {"studyType": "INTERVENTIONAL", "phases": ["PHASE3"], "designInfo": {"allocation": "RANDOMIZED", "interventionModel": "PARALLEL", "primaryPurpose": "TREATMENT", "maskingInfo": {"masking": "DOUBLE", "whoMasked": ["PARTICIPANT", "INVESTIGATOR"]}}, "enrollmentInfo": {"count": 746, "type": "ACTUAL"}}, "armsInterventionsModule": {"armGroups": [{"label": "Sitagliptin", "type": "EXPERIMENTAL", "description": "Sitagliptin 100 mg, oral, once daily for 30 weeks", "interventionNames": ["Drug: Sitagliptin", "Drug: Metformin", "Drug: Metformin XR", "Drug: Insulin glargine"]}, {"label": "Placebo", "type": "PLACEBO_COMPARATOR", "description": "Placebo to sitagliptin, 100 mg, oral, once daily for 30 weeks", "interventionNames": ["Drug: Placebo to sitagliptin", "Drug: Metformin", "Drug: Metformin XR", "Drug: Insulin glargine"]}], "interventions": [{"type": "DRUG", "name": "Sitagliptin", "description": "Sitagliptin 100 mg, oral, once daily for 30 weeks", "armGroupLabels": ["Sitagliptin"], "otherNames": ["Januvia\u00ae"]}, {"type": "DRUG", "name": "Placebo to sitagliptin", "description": "Placebo to sitagliptin, 100 mg, oral, once daily for 30 weeks", "armGroupLabels": ["Placebo"]}, {"type": "DRUG", "name": "Metformin", "description": "At least 1500 mg/day, oral, twice daily for participants entering the study on immediate-release metformin + sitagliptin or a fixed dose combination (FDC).", "armGroupLabels": ["Placebo", "Sitagliptin"]}, {"type": "DRUG", "name": "Metformin XR", "description": "At least 1500 mg/day, oral, once daily for participants entering the study on extended-release metformin + sitagliptin or a FDC.", "armGroupLabels": ["Placebo", "Sitagliptin"]}, {"type": "DRUG", "name": "Insulin glargine", "description": "Insulin glargine (LANTUS\u00ae) initiated at 10 units and titrated based on a treat-to-target algorithm to achieve fasting glucose levels of 72-100 mg/dL (4-5.6 mmol/L); administered once daily subcutaneously.", "armGroupLabels": ["Placebo", "Sitagliptin"], "otherNames": ["LANTUS\u00ae)"]}]}, "outcomesModule": {"primaryOutcomes": [{"measure": "Change From Baseline in A1C at Week 30", "description": "A1C is blood marker used to report average blood glucose levels over prolonged periods of time. Percentage A1C is the ratio of glycated hemoglobin to total hemoglobin x 100. Thus, this change from baseline reflects the Week 30 A1C minus the Week 0 A1C.", "timeFrame": "Baseline and Week 30"}, {"measure": "Event Rate of Documented Symptomatic Hypoglycemia With Blood Glucose \u226470 mg/dL (\u22643.9 mmol/L)", "description": "Documented symptomatic hypoglycemia is defined as an event during which typical symptoms of hypoglycemia are accompanied by a measured (e.g., by fingerstick) plasma glucose concentration \u226470 mg/dL (\u22643.9 mmol/L). The event rate was the total number of events divided by follow-up time (participant-years), including multiple events from the same participant.", "timeFrame": "Up to 30 weeks"}, {"measure": "Percentage of Participants Who Discontinued Study Drug Due to an AE", "description": "An AE is defined as any unfavorable and unintended sign including an abnormal laboratory finding, symptom or disease associated with the use of a medical treatment or procedure, regardless of whether it is considered related to the medical treatment or procedure, that occurs during the course of the study.", "timeFrame": "Up to 30 weeks"}, {"measure": "Percentage of Participants Who Experienced One or More Adverse Events (AEs)", "description": "An AE is defined as any unfavorable and unintended sign including an abnormal laboratory finding, symptom or disease associated with the use of a medical treatment or procedure, regardless of whether it is considered related to the medical treatment or procedure, that occurs during the course of the study.", "timeFrame": "Up to 32 weeks"}], "secondaryOutcomes": [{"measure": "Percentage of Participants With Events of Documented Symptomatic Hypoglycemia With Blood Glucose \u226470 mg/dL (\u22643.9 mmol/L)", "description": "Documented symptomatic hypoglycemia is defined as an event during which typical symptoms of hypoglycemia are accompanied by a measured (e.g., by fingerstick) plasma glucose concentration \u226470 mg/dL (\u22643.9 mmol/L). The incidence (number of participants with \u22651 event divided by number of participants) of documented symptomatic hypoglycemia was determined.", "timeFrame": "Up to 30 weeks"}, {"measure": "Change From Baseline in Total Daily Insulin Dose (Units) at Week 30", "description": "Change from baseline reflects the Week 30 total daily insulin dose minus the Week 0 total daily insulin dose. The Week 0 total daily insulin dose was 0, by definition, because insulin was not administered at baseline.", "timeFrame": "Baseline and Week 30"}, {"measure": "Event Rate of Documented Hypoglycemia With Blood Glucose \u226470 mg/dL (\u22643.9 mmol/L)", "description": "Documented hypoglycemia is defined by a measured (e.g., by fingerstick) plasma glucose concentration \u226470 mg/dL (\u22643.9 mmol/L). The event rate was the total number of events divided by follow-up time (participant-years), including multiple events from the same participant.", "timeFrame": "Up to 30 weeks"}, {"measure": "Event Rate of Documented Hypoglycemia With Blood Glucose <56 mg/dL (\u22643.1 mmol/L)", "description": "Documented hypoglycemia is defined by a measured (e.g., by fingerstick) plasma glucose concentration \\<56 mg/dL (\u22643.1 mmol/L). The event rate was the total number of events divided by follow-up time (participant-years), including multiple events from the same participant.", "timeFrame": "Up to 30 weeks"}, {"measure": "Percentage of Participants With Documented Hypoglycemia With Blood Glucose <56 mg/dL (\u22643.1 mmol/L)", "description": "Documented hypoglycemia is defined by a measured (e.g., by fingerstick) plasma glucose concentration \\<56 mg/dL (\u22643.1 mmol/L).", "timeFrame": "Up to 30 weeks"}, {"measure": "Percentage of Participants With A1C Goal <7.0% (<53 mmol/Mol) at Week 30", "description": "A1C is blood marker used to report average blood glucose levels over prolonged periods of time. Percentage A1C is the ratio of glycated hemoglobin to total hemoglobin x 100.", "timeFrame": "Week 30"}, {"measure": "Change From Baseline in Fasting Plasma Glucose (FPG) at Week 30", "description": "Blood glucose was measured on a fasting basis. Blood was drawn at predose on Day 1 and after 30 weeks of treatment to determine change in plasma glucose levels (i.e., FPG at Week 30 minus FPG at Week 0).", "timeFrame": "Baseline and Week 30"}, {"measure": "Event Rate of Documented Symptomatic Hypoglycemia With Blood Glucose <56 mg/dL (\u22643.1 mmol/L)", "description": "Documented symptomatic hypoglycemia is defined as an event during which typical symptoms of hypoglycemia are accompanied by a measured (e.g., by fingerstick) plasma glucose concentration \\<56 mg/dL (\u22643.1 mmol/L). The event rate was the total number of events divided by follow-up time (participant-years), including multiple events from the same participant.", "timeFrame": "Up to 30 weeks"}, {"measure": "Percentage of Participants With Documented Hypoglycemia With Blood Glucose \u226470 mg/dL (\u22643.9 mmol/L)", "description": "Documented hypoglycemia is defined by a measured (e.g., by fingerstick) plasma glucose concentration \u226470 mg/dL (\u22643.9 mmol/L).", "timeFrame": "Up to 30 weeks"}, {"measure": "Percentage of Participants With Documented Symptomatic Hypoglycemia With Blood Glucose <56 mg/dL (\u22643.1 mmol/L)", "description": "Documented symptomatic hypoglycemia is defined as an event during which typical symptoms of hypoglycemia are accompanied by a measured (e.g., by fingerstick) plasma glucose concentration \\<56 mg/dL (\u22643.1 mmol/L).", "timeFrame": "Up to 30 weeks"}, {"measure": "Percentage of Participants With A1C Goal <7.0% (<53 mmol/Mol at Week 30 and No Documented Hypoglycemia With Blood Glucose \u226470 mg/dL (\u22643.9 mmol/L) up to Week 30", "description": "A1C is blood marker used to report average blood glucose levels over prolonged periods of time. Percentage A1C is the ratio of glycated hemoglobin to total hemoglobin x 100.", "timeFrame": "Week 30"}]}, "eligibilityModule": {"eligibilityCriteria": "Inclusion Criteria:\n\n* Have T2DM based on American Diabetes Association guidelines\n* Be on one of the following treatment regimens:\n\n  1. Stable dose of sitagliptin (100 mg/day) and metformin IR or XR (metformin) (\u22651500 mg/day) either co-administered or as a fixed dose combination (FDC) for \u226512 weeks with A1C between 7.5% and 11.0%, inclusive.\n\n     OR\n  2. Stable dose of metformin (\u22651500 mg/day) and another dipeptidyl peptidase-4 (DPP-4) inhibitor (at maximum labeled dose, other than sitagliptin, either co-administered or as a FDC, for \u226512 weeks with A1C between 7.5% and 11.0%, inclusive.\n\n     OR\n  3. Stable dose of sitagliptin (100 mg/day) and metformin (\u22651500 mg/day) either co administered or as a FDC, and a sulfonylurea for \u226512 weeks OR stable dose of metformin (\u22651500 mg/day) and a sulfonylurea administered as a FDC and sitagliptin (100 mg/day) with A1C between 7.0% and 10.0%, inclusive.\n\n     OR\n  4. Stable dose of metformin (\u22651500 mg/day) and another DPP-4 inhibitor (at maximum labeled dose), other than sitagliptin, either co-administered or as a FDC, and a sulfonylurea for \u226512 weeks OR stable dose of metformin (\u22651500 mg/day) and a sulfonylurea administered as a FDC and another DPP-4 inhibitor other than sitagliptin with A1C between 7.0% and 10.0%, inclusive OR\n  5. Stable dose of metformin (\u22651500 mg/day) and a sulfonylurea either co-administered or as a FDC for \u226512 weeks with A1C between 7.5% and 11.0%, inclusive.\n* Meet one of the following categories:\n\n  1. The participant is a male\n  2. The participant is a female who is not of reproductive potential\n  3. The participant is a female who is of reproductive potential and agrees to avoid becoming pregnant while receiving study drug and for 14 days after the last dose of study drug by practicing abstinence from heterosexual activity OR use (or have her partner use) acceptable contraception during heterosexual activity\n\nExclusion Criteria:\n\n* Has been treated with any anti-hyperglycemic agent (AHA) other than protocol-specified agents (i.e., other than metformin, DPP-4 inhibitor, or sulfonylurea agent) within the prior 12 weeks.\n* Has a history of 2 or more episodes of hypoglycemia resulting in seizure, coma, or loss of consciousness, OR has had recurrent (\u22653 times per week) episodes of hypoglycemia over the past 8 weeks.\n* Has a history of type 1 diabetes mellitus (T1DM) or ketoacidosis, or has a history of latent autoimmune diabetes of adults (LADA), is assessed by the investigator as possibly having T1DM or LADA confirmed with a C-peptide \\<0.7 ng/mL (\\<0.23 nmol/L), or has a history of other specific types of diabetes (e.g., genetic syndromes, secondary pancreatic diabetes, diabetes due to endocrinopathies, drug- or chemical-induced, or post-organ transplant).\n* Is assessed by the investigator to be not appropriate for, or does not agree to target, a fasting glucose of 72-100 mg/dL (4.0-5.6 mmol/L).", "healthyVolunteers": false, "sex": "ALL", "minimumAge": "18 Years", "stdAges": ["ADULT", "OLDER_ADULT"]}, "contactsLocationsModule": {"overallOfficials": [{"name": "Medical Director", "affiliation": "Merck Sharp & Dohme LLC", "role": "STUDY_DIRECTOR"}]}, "referencesModule": {"references": [{"pmid": "30393950", "type": "DERIVED", "citation": "Roussel R, Duran-Garcia S, Zhang Y, Shah S, Darmiento C, Shankar RR, Golm GT, Lam RLH, O'Neill EA, Gantz I, Kaufman KD, Engel SS. Double-blind, randomized clinical trial comparing the efficacy and safety of continuing or discontinuing the dipeptidyl peptidase-4 inhibitor sitagliptin when initiating insulin glargine therapy in patients with type 2 diabetes: The CompoSIT-I Study. Diabetes Obes Metab. 2019 Apr;21(4):781-790. doi: 10.1111/dom.13574. Epub 2018 Dec 9."}]}, "ipdSharingStatementModule": {"ipdSharing": "YES", "description": "http://engagezone.msd.com/doc/ProcedureAccessClinicalTrialData.pdf", "url": "http://engagezone.msd.com/ds_documentation.php"}}, "resultsSection": {"participantFlowModule": {"preAssignmentDetails": "Male and female participants with Type 2 diabetes mellitus (T2DM) \u226518 years of age were enrolled in this trial.", "recruitmentDetails": "A total of 746 participants were randomized across 149 study sites in 22 countries.", "groups": [{"id": "FG000", "title": "Sitagliptin", "description": "Sitagliptin 100 mg, oral, once daily for 30 weeks"}, {"id": "FG001", "title": "Placebo", "description": "Placebo to sitagliptin, 100 mg, oral, once daily for 30 weeks"}], "periods": [{"title": "Overall Study", "milestones": [{"type": "STARTED", "achievements": [{"groupId": "FG000", "numSubjects": "374"}, {"groupId": "FG001", "numSubjects": "372"}]}, {"type": "Treated", "achievements": [{"groupId": "FG000", "numSubjects": "373"}, {"groupId": "FG001", "numSubjects": "370"}]}, {"type": "COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "361"}, {"groupId": "FG001", "numSubjects": "347"}]}, {"type": "NOT COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "13"}, {"groupId": "FG001", "numSubjects": "25"}]}], "dropWithdraws": [{"type": "Adverse Event", "reasons": [{"groupId": "FG000", "numSubjects": "1"}, {"groupId": "FG001", "numSubjects": "1"}]}, {"type": "Death", "reasons": [{"groupId": "FG000", "numSubjects": "0"}, {"groupId": "FG001", "numSubjects": "2"}]}, {"type": "Lost to Follow-up", "reasons": [{"groupId": "FG000", "numSubjects": "1"}, {"groupId": "FG001", "numSubjects": "5"}]}, {"type": "Protocol Violation", "reasons": [{"groupId": "FG000", "numSubjects": "1"}, {"groupId": "FG001", "numSubjects": "3"}]}, {"type": "Physician Decision", "reasons": [{"groupId": "FG000", "numSubjects": "3"}, {"groupId": "FG001", "numSubjects": "4"}]}, {"type": "Pregnancy", "reasons": [{"groupId": "FG000", "numSubjects": "0"}, {"groupId": "FG001", "numSubjects": "1"}]}, {"type": "Screen Failure", "reasons": [{"groupId": "FG000", "numSubjects": "1"}, {"groupId": "FG001", "numSubjects": "2"}]}, {"type": "Site Discontinued Study Participation", "reasons": [{"groupId": "FG000", "numSubjects": "1"}, {"groupId": "FG001", "numSubjects": "0"}]}, {"type": "Withdrawal by Subject", "reasons": [{"groupId": "FG000", "numSubjects": "5"}, {"groupId": "FG001", "numSubjects": "7"}]}]}]}, "baselineCharacteristicsModule": {"populationDescription": "The overall number of baseline participants included all randomized participants.", "groups": [{"id": "BG000", "title": "Sitagliptin", "description": "Sitagliptin 100 mg, oral, once daily for 30 weeks"}, {"id": "BG001", "title": "Placebo", "description": "Placebo to sitagliptin 100 mg, oral, once daily for 30 weeks"}, {"id": "BG002", "title": "Total", "description": "Total of all reporting groups"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "BG000", "value": "374"}, {"groupId": "BG001", "value": "372"}, {"groupId": "BG002", "value": "746"}]}], "measures": [{"title": "Age, Continuous", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "years", "classes": [{"denoms": [{"units": "Participants", "counts": [{"groupId": "BG000", "value": "374"}, {"groupId": "BG001", "value": "372"}, {"groupId": "BG002", "value": "746"}]}], "categories": [{"measurements": [{"groupId": "BG000", "value": "58.5", "spread": "9.5"}, {"groupId": "BG001", "value": "58.1", "spread": "9.7"}, {"groupId": "BG002", "value": "58.3", "spread": "9.6"}]}]}]}, {"title": "Age, Customized", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"denoms": [{"units": "Participants", "counts": [{"groupId": "BG000", "value": "374"}, {"groupId": "BG001", "value": "372"}, {"groupId": "BG002", "value": "746"}]}], "categories": [{"title": "In utero", "measurements": [{"groupId": "BG000", "value": "0"}, {"groupId": "BG001", "value": "0"}, {"groupId": "BG002", "value": "0"}]}, {"title": "Preterm newborn infants (gestational age < 37 wks)", "measurements": [{"groupId": "BG000", "value": "0"}, {"groupId": "BG001", "value": "0"}, {"groupId": "BG002", "value": "0"}]}, {"title": "Newborns (0-27 days)", "measurements": [{"groupId": "BG000", "value": "0"}, {"groupId": "BG001", "value": "0"}, {"groupId": "BG002", "value": "0"}]}, {"title": "Infants and toddlers (28 days-23 months)", "measurements": [{"groupId": "BG000", "value": "0"}, {"groupId": "BG001", "value": "0"}, {"groupId": "BG002", "value": "0"}]}, {"title": "Children (2-11 years)", "measurements": [{"groupId": "BG000", "value": "0"}, {"groupId": "BG001", "value": "0"}, {"groupId": "BG002", "value": "0"}]}, {"title": "Adolescents (12-17 years)", "measurements": [{"groupId": "BG000", "value": "0"}, {"groupId": "BG001", "value": "0"}, {"groupId": "BG002", "value": "0"}]}, {"title": "Adults (18-64 years)", "measurements": [{"groupId": "BG000", "value": "275"}, {"groupId": "BG001", "value": "272"}, {"groupId": "BG002", "value": "547"}]}, {"title": "From 65-84 years", "measurements": [{"groupId": "BG000", "value": "99"}, {"groupId": "BG001", "value": "100"}, {"groupId": "BG002", "value": "199"}]}, {"title": "85 years and over", "measurements": [{"groupId": "BG000", "value": "0"}, {"groupId": "BG001", "value": "0"}, {"groupId": "BG002", "value": "0"}]}]}]}, {"title": "Sex: Female, Male", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"denoms": [{"units": "Participants", "counts": [{"groupId": "BG000", "value": "374"}, {"groupId": "BG001", "value": "372"}, {"groupId": "BG002", "value": "746"}]}], "categories": [{"title": "Female", "measurements": [{"groupId": "BG000", "value": "204"}, {"groupId": "BG001", "value": "181"}, {"groupId": "BG002", "value": "385"}]}, {"title": "Male", "measurements": [{"groupId": "BG000", "value": "170"}, {"groupId": "BG001", "value": "191"}, {"groupId": "BG002", "value": "361"}]}]}]}, {"title": "Race (NIH/OMB)", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"denoms": [{"units": "Participants", "counts": [{"groupId": "BG000", "value": "374"}, {"groupId": "BG001", "value": "372"}, {"groupId": "BG002", "value": "746"}]}], "categories": [{"title": "American Indian or Alaska Native", "measurements": [{"groupId": "BG000", "value": "19"}, {"groupId": "BG001", "value": "18"}, {"groupId": "BG002", "value": "37"}]}, {"title": "Asian", "measurements": [{"groupId": "BG000", "value": "42"}, {"groupId": "BG001", "value": "37"}, {"groupId": "BG002", "value": "79"}]}, {"title": "Native Hawaiian or Other Pacific Islander", "measurements": [{"groupId": "BG000", "value": "6"}, {"groupId": "BG001", "value": "1"}, {"groupId": "BG002", "value": "7"}]}, {"title": "Black or African American", "measurements": [{"groupId": "BG000", "value": "12"}, {"groupId": "BG001", "value": "12"}, {"groupId": "BG002", "value": "24"}]}, {"title": "White", "measurements": [{"groupId": "BG000", "value": "259"}, {"groupId": "BG001", "value": "270"}, {"groupId": "BG002", "value": "529"}]}, {"title": "More than one race", "measurements": [{"groupId": "BG000", "value": "34"}, {"groupId": "BG001", "value": "34"}, {"groupId": "BG002", "value": "68"}]}, {"title": "Unknown or Not Reported", "measurements": [{"groupId": "BG000", "value": "2"}, {"groupId": "BG001", "value": "0"}, {"groupId": "BG002", "value": "2"}]}]}]}, {"title": "Geographic Region", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"denoms": [{"units": "Participants", "counts": [{"groupId": "BG000", "value": "374"}, {"groupId": "BG001", "value": "372"}, {"groupId": "BG002", "value": "746"}]}], "categories": [{"title": "Asia", "measurements": [{"groupId": "BG000", "value": "36"}, {"groupId": "BG001", "value": "26"}, {"groupId": "BG002", "value": "62"}]}, {"title": "Europe", "measurements": [{"groupId": "BG000", "value": "158"}, {"groupId": "BG001", "value": "172"}, {"groupId": "BG002", "value": "330"}]}, {"title": "Latin America", "measurements": [{"groupId": "BG000", "value": "85"}, {"groupId": "BG001", "value": "83"}, {"groupId": "BG002", "value": "168"}]}, {"title": "North America", "measurements": [{"groupId": "BG000", "value": "80"}, {"groupId": "BG001", "value": "78"}, {"groupId": "BG002", "value": "158"}]}, {"title": "Other", "measurements": [{"groupId": "BG000", "value": "15"}, {"groupId": "BG001", "value": "13"}, {"groupId": "BG002", "value": "28"}]}]}]}, {"title": "Hemoglobin A1C (A1C)", "description": "Percent A1C= Glycated hemoglobin/total hemoglobin x 100", "populationDescription": "All randomized and treated participants", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "Percent A1C", "classes": [{"denoms": [{"units": "Participants", "counts": [{"groupId": "BG000", "value": "373"}, {"groupId": "BG001", "value": "370"}, {"groupId": "BG002", "value": "743"}]}], "categories": [{"measurements": [{"groupId": "BG000", "value": "8.8", "spread": "0.9"}, {"groupId": "BG001", "value": "8.8", "spread": "1.0"}, {"groupId": "BG002", "value": "8.8", "spread": "0.9"}]}]}]}, {"title": "Fasting Plasma Glucose (FPG)", "description": "Fasting plasma glucose level after a 10-hour overnight fast.", "populationDescription": "All randomized and treated participants", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "mg/dL", "classes": [{"denoms": [{"units": "Participants", "counts": [{"groupId": "BG000", "value": "373"}, {"groupId": "BG001", "value": "370"}, {"groupId": "BG002", "value": "743"}]}], "categories": [{"measurements": [{"groupId": "BG000", "value": "199.0", "spread": "50.8"}, {"groupId": "BG001", "value": "201.2", "spread": "51.8"}, {"groupId": "BG002", "value": "200.1", "spread": "51.3"}]}]}]}, {"title": "Estimated Glomerular Filtration Rate", "description": "Estimated Glomerular Filtration Rate (eGFR) is a test of renal function.", "populationDescription": "All randomized and treated participants", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "mL/min/1.73 m^2", "classes": [{"denoms": [{"units": "Participants", "counts": [{"groupId": "BG000", "value": "373"}, {"groupId": "BG001", "value": "370"}, {"groupId": "BG002", "value": "743"}]}], "categories": [{"measurements": [{"groupId": "BG000", "value": "103.7", "spread": "30.3"}, {"groupId": "BG001", "value": "106.4", "spread": "28.1"}, {"groupId": "BG002", "value": "105.1", "spread": "29.2"}]}]}]}, {"title": "Body Weight", "populationDescription": "All randomized and treated participants", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "Kilograms", "classes": [{"denoms": [{"units": "Participants", "counts": [{"groupId": "BG000", "value": "373"}, {"groupId": "BG001", "value": "370"}, {"groupId": "BG002", "value": "743"}]}], "categories": [{"measurements": [{"groupId": "BG000", "value": "84.8", "spread": "19.8"}, {"groupId": "BG001", "value": "85.6", "spread": "18.9"}, {"groupId": "BG002", "value": "85.2", "spread": "19.4"}]}]}]}, {"title": "Anti-Hyperglycemic Agent", "description": "Background Anti-Hyperglycemic Agent (AHA) at Screening metformin = Met) dipeptidyl peptidase 4 inhibitor = DPP-4i", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"denoms": [{"units": "Participants", "counts": [{"groupId": "BG000", "value": "374"}, {"groupId": "BG001", "value": "372"}, {"groupId": "BG002", "value": "746"}]}], "categories": [{"title": "Met + DPP-4i", "measurements": [{"groupId": "BG000", "value": "184"}, {"groupId": "BG001", "value": "184"}, {"groupId": "BG002", "value": "368"}]}, {"title": "Met + DPP-4i + sulfonylurea (SU)", "measurements": [{"groupId": "BG000", "value": "87"}, {"groupId": "BG001", "value": "86"}, {"groupId": "BG002", "value": "173"}]}, {"title": "Met + SU", "measurements": [{"groupId": "BG000", "value": "103"}, {"groupId": "BG001", "value": "102"}, {"groupId": "BG002", "value": "205"}]}]}]}]}, "outcomeMeasuresModule": {"outcomeMeasures": [{"type": "PRIMARY", "title": "Change From Baseline in A1C at Week 30", "description": "A1C is blood marker used to report average blood glucose levels over prolonged periods of time. Percentage A1C is the ratio of glycated hemoglobin to total hemoglobin x 100. Thus, this change from baseline reflects the Week 30 A1C minus the Week 0 A1C.", "populationDescription": "All randomized participants who received at least one dose of study treatment and had at least one measurement of the respective endpoint (baseline or post-baseline).", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "95% Confidence Interval", "unitOfMeasure": "Percent A1C", "timeFrame": "Baseline and Week 30", "groups": [{"id": "OG000", "title": "Sitagliptin", "description": "Sitagliptin 100 mg, oral, once daily for 30 weeks"}, {"id": "OG001", "title": "Placebo", "description": "Placebo to sitagliptin, 100 mg, oral, once daily for 30 weeks"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "373"}, {"groupId": "OG001", "value": "370"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "-1.88", "spread": "-1.98", "lowerLimit": "-1.98", "upperLimit": "-1.78"}, {"groupId": "OG001", "value": "-1.42", "spread": "-1.52", "lowerLimit": "-1.52", "upperLimit": "-1.32"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "groupDescription": "A longitudinal data analysis (LDA) model included terms for treatment, AHA treatment at screening (Met + DPP-4i, Met + DPP-4i + SU, Met + SU), time, and the interactions of time by treatment and of time by AHA treatment at screening. Least Squares Means = LSM", "nonInferiorityType": "NON_INFERIORITY", "nonInferiorityComment": "Hypothesis A: After 30 weeks, continuing sitagliptin is non-inferior relative to withdrawing sitagliptin on the change from baseline in A1C. Non-inferiority is declared if the upper bound of the two-sided 95% CI for the difference is less than 0.3%.", "statisticalMethod": "LDA", "paramType": "Between Group Difference in the LSM", "paramValue": "-0.46", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-0.58", "ciUpperLimit": "-0.34"}, {"groupIds": ["OG000", "OG001"], "groupDescription": "A LDA model included terms for treatment, AHA treatment at screening (Met + DPP-4i, Met + DPP-4i + SU, Met + SU), time, and the interactions of time by treatment and of time by AHA treatment at screening.", "nonInferiorityType": "SUPERIORITY", "nonInferiorityComment": "Hypothesis B: After 30 weeks, continuing sitagliptin results in a greater reduction of A1C relative to withdrawing sitagliptin.", "pValue": "< 0.001", "statisticalMethod": "LDA", "paramType": "Between Group Difference in the LSM", "paramValue": "-0.46", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-0.58", "ciUpperLimit": "-0.34"}]}, {"type": "PRIMARY", "title": "Event Rate of Documented Symptomatic Hypoglycemia With Blood Glucose \u226470 mg/dL (\u22643.9 mmol/L)", "description": "Documented symptomatic hypoglycemia is defined as an event during which typical symptoms of hypoglycemia are accompanied by a measured (e.g., by fingerstick) plasma glucose concentration \u226470 mg/dL (\u22643.9 mmol/L). The event rate was the total number of events divided by follow-up time (participant-years), including multiple events from the same participant.", "populationDescription": "All randomized participants who received at least one dose of study treatment. Two participants in the sitagliptin group were not included in the primary analysis due to a missing value of a model covariate (race).", "reportingStatus": "POSTED", "paramType": "NUMBER", "dispersionType": "95% Confidence Interval", "unitOfMeasure": "Events/Participant-Years", "timeFrame": "Up to 30 weeks", "groups": [{"id": "OG000", "title": "Sitagliptin", "description": "Sitagliptin 100 mg, oral, once daily for 30 weeks"}, {"id": "OG001", "title": "Placebo", "description": "Placebo to sitagliptin, 100 mg, oral, once daily for 30 weeks"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "371"}, {"groupId": "OG001", "value": "370"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "1.55", "spread": "1.22", "lowerLimit": "1.22", "upperLimit": "1.96"}, {"groupId": "OG001", "value": "2.12", "spread": "1.70", "lowerLimit": "1.70", "upperLimit": "2.66"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "groupDescription": "Calculated via the Negative Binomial Model including terms for treatment, race (i.e., White and Other), region (i.e., Europe, North America, and Other), AHA treatment at screening, baseline A1C value and baseline body weight and an offset for follow-up time (on the natural log scale).", "nonInferiorityType": "SUPERIORITY", "pValue": "= 0.039", "statisticalMethod": "Negative Binomial Model", "paramType": "Event Rate Ratio", "paramValue": "0.73", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "0.54", "ciUpperLimit": "0.98"}]}, {"type": "PRIMARY", "title": "Percentage of Participants Who Discontinued Study Drug Due to an AE", "description": "An AE is defined as any unfavorable and unintended sign including an abnormal laboratory finding, symptom or disease associated with the use of a medical treatment or procedure, regardless of whether it is considered related to the medical treatment or procedure, that occurs during the course of the study.", "populationDescription": "All randomized participants who received at least one dose of study treatment.", "reportingStatus": "POSTED", "paramType": "NUMBER", "unitOfMeasure": "Percentage of participants", "timeFrame": "Up to 30 weeks", "groups": [{"id": "OG000", "title": "Sitagliptin", "description": "Sitagliptin 100 mg, oral, once daily for 30 weeks"}, {"id": "OG001", "title": "Placebo", "description": "Placebo to sitagliptin, 100 mg, oral, once daily for 30 weeks"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "373"}, {"groupId": "OG001", "value": "370"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "1.3"}, {"groupId": "OG001", "value": "1.6"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "nonInferiorityType": "OTHER", "nonInferiorityComment": "95% CI", "statisticalMethod": "Miettinen & Nurminen", "paramType": "Between Group Difference in Percentages", "paramValue": "-0.3", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-2.3", "ciUpperLimit": "1.7"}]}, {"type": "SECONDARY", "title": "Percentage of Participants With Events of Documented Symptomatic Hypoglycemia With Blood Glucose \u226470 mg/dL (\u22643.9 mmol/L)", "description": "Documented symptomatic hypoglycemia is defined as an event during which typical symptoms of hypoglycemia are accompanied by a measured (e.g., by fingerstick) plasma glucose concentration \u226470 mg/dL (\u22643.9 mmol/L). The incidence (number of participants with \u22651 event divided by number of participants) of documented symptomatic hypoglycemia was determined.", "populationDescription": "All randomized participants who received at least one dose of study treatment.", "reportingStatus": "POSTED", "paramType": "NUMBER", "dispersionType": "95% Confidence Interval", "unitOfMeasure": "Percentage of participants", "timeFrame": "Up to 30 weeks", "groups": [{"id": "OG000", "title": "Sitagliptin", "description": "Sitagliptin 100 mg, oral, once daily for 30 weeks"}, {"id": "OG001", "title": "Placebo", "description": "Placebo to sitagliptin, 100 mg, oral, once daily for 30 weeks"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "373"}, {"groupId": "OG001", "value": "370"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "33.5", "spread": "28.5", "lowerLimit": "28.5", "upperLimit": "38.6"}, {"groupId": "OG001", "value": "37.7", "spread": "32.7", "lowerLimit": "32.7", "upperLimit": "42.6"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "nonInferiorityType": "SUPERIORITY", "pValue": "= 0.250", "statisticalMethod": "Miettinen and Nurminen", "paramType": "Between Group Difference in Percentages", "paramValue": "-4.1", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-11.2", "ciUpperLimit": "2.9"}]}, {"type": "SECONDARY", "title": "Change From Baseline in Total Daily Insulin Dose (Units) at Week 30", "description": "Change from baseline reflects the Week 30 total daily insulin dose minus the Week 0 total daily insulin dose. The Week 0 total daily insulin dose was 0, by definition, because insulin was not administered at baseline.", "populationDescription": "All randomized participants who received at least one dose of study treatment and had at least one measurement of the respective endpoint (baseline or post-baseline).", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "95% Confidence Interval", "unitOfMeasure": "Insulin Units", "timeFrame": "Baseline and Week 30", "groups": [{"id": "OG000", "title": "Sitagliptin", "description": "Sitagliptin 100 mg, oral, once daily for 30 weeks"}, {"id": "OG001", "title": "Placebo", "description": "Placebo to sitagliptin, 100 mg, oral, once daily for 30 weeks"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "365"}, {"groupId": "OG001", "value": "367"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "53.2", "spread": "48.5", "lowerLimit": "48.5", "upperLimit": "58.0"}, {"groupId": "OG001", "value": "61.3", "spread": "56.5", "lowerLimit": "56.5", "upperLimit": "66.0"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "groupDescription": "The analysis is based on a LDA model including terms for treatment, AHA treatment at screening (Met + DPP-4i, Met + DPP-4i + SU, Met + SU), time, and the interactions of time by treatment and of time by AHA treatment at screening.", "nonInferiorityType": "SUPERIORITY", "pValue": "= 0.016", "statisticalMethod": "LDA model", "paramType": "Between Group Difference in the LSM", "paramValue": "-8.0", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-14.6", "ciUpperLimit": "-1.5"}]}, {"type": "SECONDARY", "title": "Event Rate of Documented Hypoglycemia With Blood Glucose \u226470 mg/dL (\u22643.9 mmol/L)", "description": "Documented hypoglycemia is defined by a measured (e.g., by fingerstick) plasma glucose concentration \u226470 mg/dL (\u22643.9 mmol/L). The event rate was the total number of events divided by follow-up time (participant-years), including multiple events from the same participant.", "populationDescription": "All randomized participants who received at least one dose of study treatment and had at least one measurement of the respective endpoint (baseline or post-baseline). Two participants (both in the sitagliptin group) were not included in the analysis due to a missing value of a model covariate (race).", "reportingStatus": "POSTED", "paramType": "NUMBER", "dispersionType": "95% Confidence Interval", "unitOfMeasure": "Events/Participant-Years", "timeFrame": "Up to 30 weeks", "groups": [{"id": "OG000", "title": "Sitagliptin", "description": "Sitagliptin 100 mg, oral, once daily for 30 weeks"}, {"id": "OG001", "title": "Placebo", "description": "Placebo to sitagliptin, 100 mg, oral, once daily for 30 weeks"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "371"}, {"groupId": "OG001", "value": "370"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "5.05", "spread": "4.34", "lowerLimit": "4.34", "upperLimit": "5.88"}, {"groupId": "OG001", "value": "6.21", "spread": "5.33", "lowerLimit": "5.33", "upperLimit": "7.24"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "groupDescription": "Negative Binomial Model including terms for treatment, race (i.e., White and Other), region (i.e., Europe, North America, and Other), AHA treatment at screening, baseline A1C value and baseline body weight and an offset for follow-up time (on the natural log scale).", "nonInferiorityType": "SUPERIORITY", "pValue": "= 0.041", "statisticalMethod": "Negative Binomial Model", "paramType": "Event Rate Ratio", "paramValue": "0.81", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "0.67", "ciUpperLimit": "0.99"}]}, {"type": "SECONDARY", "title": "Event Rate of Documented Hypoglycemia With Blood Glucose <56 mg/dL (\u22643.1 mmol/L)", "description": "Documented hypoglycemia is defined by a measured (e.g., by fingerstick) plasma glucose concentration \\<56 mg/dL (\u22643.1 mmol/L). The event rate was the total number of events divided by follow-up time (participant-years), including multiple events from the same participant.", "populationDescription": "All randomized participants who received at least one dose of study treatment and had at least one measurement of the respective endpoint (baseline or post-baseline). Two participants (both in the sitagliptin group) were not included in the analysis due to a missing value of a model covariate (race).", "reportingStatus": "POSTED", "paramType": "NUMBER", "dispersionType": "95% Confidence Interval", "unitOfMeasure": "Events/Participant-Years", "timeFrame": "Up to 30 weeks", "groups": [{"id": "OG000", "title": "Sitagliptin", "description": "Sitagliptin 100 mg, oral, once daily for 30 weeks"}, {"id": "OG001", "title": "Placebo", "description": "Placebo to sitagliptin, 100 mg, oral, once daily for 30 weeks"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "371"}, {"groupId": "OG001", "value": "370"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "0.30", "spread": "0.20", "lowerLimit": "0.20", "upperLimit": "0.45"}, {"groupId": "OG001", "value": "0.36", "spread": "0.25", "lowerLimit": "0.25", "upperLimit": "0.53"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "groupDescription": "Negative Binomial Model including terms for treatment, race (i.e., White and Other), region (i.e., Europe, North America, and Other), AHA treatment at screening, baseline A1C value and baseline body weight and an offset for follow-up time (on the natural log scale).", "nonInferiorityType": "SUPERIORITY", "pValue": "= 0.473", "statisticalMethod": "Negative Binomial Model", "paramType": "Event Rate Ratio", "paramValue": "0.83", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "0.51", "ciUpperLimit": "1.37"}]}, {"type": "SECONDARY", "title": "Percentage of Participants With Documented Hypoglycemia With Blood Glucose <56 mg/dL (\u22643.1 mmol/L)", "description": "Documented hypoglycemia is defined by a measured (e.g., by fingerstick) plasma glucose concentration \\<56 mg/dL (\u22643.1 mmol/L).", "populationDescription": "All randomized participants who received at least one dose of study treatment.", "reportingStatus": "POSTED", "paramType": "NUMBER", "dispersionType": "95% Confidence Interval", "unitOfMeasure": "Percentage of participants", "timeFrame": "Up to 30 weeks", "groups": [{"id": "OG000", "title": "Sitagliptin", "description": "Sitagliptin 100 mg, oral, once daily for 30 weeks"}, {"id": "OG001", "title": "Placebo", "description": "Placebo to sitagliptin, 100 mg, oral, once daily for 30 weeks"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "373"}, {"groupId": "OG001", "value": "370"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "12.4", "spread": "8.9", "lowerLimit": "8.9", "upperLimit": "15.8"}, {"groupId": "OG001", "value": "13.6", "spread": "10.0", "lowerLimit": "10.0", "upperLimit": "17.2"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "groupDescription": "Percentages and difference in percentages were calculated via the Miettinen and Nurminen stratified by AHA treatment at screening. Includes imputed events after participants discontinued from the study medication, using a Gamma frailty model. The bootstrap method was used to obtain the CI and p-value.", "nonInferiorityType": "SUPERIORITY", "pValue": "= 0.624", "statisticalMethod": "Miettinen and Nurminen", "paramType": "Between Group Difference in Percentages", "paramValue": "-1.2", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-6.2", "ciUpperLimit": "3.7"}]}, {"type": "SECONDARY", "title": "Percentage of Participants With A1C Goal <7.0% (<53 mmol/Mol) at Week 30", "description": "A1C is blood marker used to report average blood glucose levels over prolonged periods of time. Percentage A1C is the ratio of glycated hemoglobin to total hemoglobin x 100.", "populationDescription": "All randomized participants who received at least one dose of study treatment.", "reportingStatus": "POSTED", "paramType": "NUMBER", "unitOfMeasure": "Percentage of participants", "timeFrame": "Week 30", "groups": [{"id": "OG000", "title": "Sitagliptin", "description": "Sitagliptin 100 mg, oral, once daily for 30 weeks"}, {"id": "OG001", "title": "Placebo", "description": "Placebo to sitagliptin, 100 mg, oral, once daily for 30 weeks"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "373"}, {"groupId": "OG001", "value": "370"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "54.2"}, {"groupId": "OG001", "value": "35.4"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "nonInferiorityType": "SUPERIORITY", "pValue": "< 0.001", "statisticalMethod": "Miettinen and Nurminen", "paramType": "Between Group Difference in Percentages", "paramValue": "18.8", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "11.6", "ciUpperLimit": "25.7"}]}, {"type": "SECONDARY", "title": "Change From Baseline in Fasting Plasma Glucose (FPG) at Week 30", "description": "Blood glucose was measured on a fasting basis. Blood was drawn at predose on Day 1 and after 30 weeks of treatment to determine change in plasma glucose levels (i.e., FPG at Week 30 minus FPG at Week 0).", "populationDescription": "All randomized participants who received at least one dose of study treatment and had at least one measurement of the respective endpoint (baseline or post-baseline).", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "95% Confidence Interval", "unitOfMeasure": "mg/dL", "timeFrame": "Baseline and Week 30", "groups": [{"id": "OG000", "title": "Sitagliptin", "description": "Sitagliptin 100 mg, oral, once daily for 30 weeks"}, {"id": "OG001", "title": "Placebo", "description": "Placebo to sitagliptin, 100 mg, oral, once daily for 30 weeks"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "373"}, {"groupId": "OG001", "value": "370"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "-84.8", "spread": "-90.0", "lowerLimit": "-90.0", "upperLimit": "-79.6"}, {"groupId": "OG001", "value": "-78.3", "spread": "-83.5", "lowerLimit": "-83.5", "upperLimit": "-73.1"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "groupDescription": "Analysis was based on a LDA model including terms for treatment, AHA treatment at screening (Met + DPP-4i, Met + DPP-4i + SU, Met + SU), time, and the interactions of time by treatment and of time by AHA treatment at screening.", "nonInferiorityType": "SUPERIORITY", "pValue": "= 0.020", "statisticalMethod": "LDA", "paramType": "Between Group Difference in the LSM", "paramValue": "-6.5", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-11.9", "ciUpperLimit": "-1.0"}]}, {"type": "PRIMARY", "title": "Percentage of Participants Who Experienced One or More Adverse Events (AEs)", "description": "An AE is defined as any unfavorable and unintended sign including an abnormal laboratory finding, symptom or disease associated with the use of a medical treatment or procedure, regardless of whether it is considered related to the medical treatment or procedure, that occurs during the course of the study.", "populationDescription": "All randomized participants who received at least one dose of study treatment.", "reportingStatus": "POSTED", "paramType": "NUMBER", "unitOfMeasure": "Percentage of participants", "timeFrame": "Up to 32 weeks", "groups": [{"id": "OG000", "title": "Sitagliptin", "description": "Sitagliptin 100 mg, oral, once daily for 30 weeks"}, {"id": "OG001", "title": "Placebo", "description": "Placebo to sitagliptin, 100 mg, oral, once daily for 30 weeks"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "373"}, {"groupId": "OG001", "value": "370"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "57.9"}, {"groupId": "OG001", "value": "60.0"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "nonInferiorityType": "OTHER", "nonInferiorityComment": "95% CI", "statisticalMethod": "Miettinen & Nurminen", "paramType": "Between Group Difference in Percentages", "paramValue": "-2.1", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-9.1", "ciUpperLimit": "5.0"}]}, {"type": "SECONDARY", "title": "Event Rate of Documented Symptomatic Hypoglycemia With Blood Glucose <56 mg/dL (\u22643.1 mmol/L)", "description": "Documented symptomatic hypoglycemia is defined as an event during which typical symptoms of hypoglycemia are accompanied by a measured (e.g., by fingerstick) plasma glucose concentration \\<56 mg/dL (\u22643.1 mmol/L). The event rate was the total number of events divided by follow-up time (participant-years), including multiple events from the same participant.", "populationDescription": "All randomized participants who received at least one dose of study treatment. Two participants in the sitagliptin group were not included in the primary analysis due to a missing value of a model covariate (race).", "reportingStatus": "POSTED", "paramType": "NUMBER", "dispersionType": "95% Confidence Interval", "unitOfMeasure": "Events/Participant-Years", "timeFrame": "Up to 30 weeks", "groups": [{"id": "OG000", "title": "Sitagliptin", "description": "Sitagliptin 100 mg, oral, once daily for 30 weeks"}, {"id": "OG001", "title": "Placebo", "description": "Placebo to sitagliptin, 100 mg, oral, once daily for 30 weeks"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "371"}, {"groupId": "OG001", "value": "370"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "0.17", "spread": "0.10", "lowerLimit": "0.10", "upperLimit": "0.28"}, {"groupId": "OG001", "value": "0.22", "spread": "0.14", "lowerLimit": "0.14", "upperLimit": "0.36"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "groupDescription": "The analysis was calculated via the Negative Binomial Model including terms for treatment, race (i.e., White and Other), region (i.e., Europe, North America, and Other), AHA treatment at screening, baseline A1C value and baseline body weight and an offset for follow-up time (on the natural log scale).", "nonInferiorityType": "SUPERIORITY", "pValue": "= 0.394", "statisticalMethod": "Negative Binomial Model", "paramType": "Event Rate Ratio", "paramValue": "0.76", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "0.40", "ciUpperLimit": "1.44"}]}, {"type": "SECONDARY", "title": "Percentage of Participants With Documented Hypoglycemia With Blood Glucose \u226470 mg/dL (\u22643.9 mmol/L)", "description": "Documented hypoglycemia is defined by a measured (e.g., by fingerstick) plasma glucose concentration \u226470 mg/dL (\u22643.9 mmol/L).", "populationDescription": "All randomized participants who received at least one dose of study treatment.", "reportingStatus": "POSTED", "paramType": "NUMBER", "dispersionType": "95% Confidence Interval", "unitOfMeasure": "Percentage of participants", "timeFrame": "Up to 30 weeks", "groups": [{"id": "OG000", "title": "Sitagliptin", "description": "Sitagliptin 100 mg, oral, once daily for 30 weeks"}, {"id": "OG001", "title": "Placebo", "description": "Placebo to sitagliptin, 100 mg, oral, once daily for 30 weeks"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "373"}, {"groupId": "OG001", "value": "370"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "66.8", "spread": "61.9", "lowerLimit": "61.9", "upperLimit": "71.7"}, {"groupId": "OG001", "value": "68.0", "spread": "63.2", "lowerLimit": "63.2", "upperLimit": "72.9"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "groupDescription": "The analysis included imputed events after participants discontinued from the study medication, using a Gamma frailty model. Proportions and difference in proportions were calculated via the Miettinen and Nurminen stratified by AHA treatment at screening. The bootstrap method was used to obtain the CI and p-value.", "nonInferiorityType": "SUPERIORITY", "pValue": "= 0.740", "statisticalMethod": "Miettinen and Nurminen", "paramType": "Between Group Difference in Percentages", "paramValue": "-1.2", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-8.2", "ciUpperLimit": "5.8"}]}, {"type": "SECONDARY", "title": "Percentage of Participants With Documented Symptomatic Hypoglycemia With Blood Glucose <56 mg/dL (\u22643.1 mmol/L)", "description": "Documented symptomatic hypoglycemia is defined as an event during which typical symptoms of hypoglycemia are accompanied by a measured (e.g., by fingerstick) plasma glucose concentration \\<56 mg/dL (\u22643.1 mmol/L).", "populationDescription": "All randomized participants who received at least one dose of study treatment.", "reportingStatus": "POSTED", "paramType": "NUMBER", "dispersionType": "95% Confidence Interval", "unitOfMeasure": "Percentage of participants", "timeFrame": "Up to 30 weeks", "groups": [{"id": "OG000", "title": "Sitagliptin", "description": "Sitagliptin 100 mg, oral, once daily for 30 weeks"}, {"id": "OG001", "title": "Placebo", "description": "Placebo to sitagliptin, 100 mg, oral, once daily for 30 weeks"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "373"}, {"groupId": "OG001", "value": "370"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "7.6", "spread": "4.9", "lowerLimit": "4.9", "upperLimit": "10.3"}, {"groupId": "OG001", "value": "8.3", "spread": "5.4", "lowerLimit": "5.4", "upperLimit": "11.2"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "groupDescription": "Percentages and difference in percentages were calculated via the Miettinen and Nurminen stratified by AHA treatment at screening. The analysis included imputed events after subjects discontinued from the study medication, using a Gamma frailty model. The bootstrap method was used to obtain the CI and p-value.", "nonInferiorityType": "SUPERIORITY", "pValue": "= 0.712", "statisticalMethod": "Miettinen and Nurminen", "paramType": "Between Group Difference in Percentages", "paramValue": "-0.7", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-4.7", "ciUpperLimit": "3.2"}]}, {"type": "SECONDARY", "title": "Percentage of Participants With A1C Goal <7.0% (<53 mmol/Mol at Week 30 and No Documented Hypoglycemia With Blood Glucose \u226470 mg/dL (\u22643.9 mmol/L) up to Week 30", "description": "A1C is blood marker used to report average blood glucose levels over prolonged periods of time. Percentage A1C is the ratio of glycated hemoglobin to total hemoglobin x 100.", "populationDescription": "All randomized participants who received at least one dose of study treatment.", "reportingStatus": "POSTED", "paramType": "NUMBER", "unitOfMeasure": "Percentage of participants", "timeFrame": "Week 30", "groups": [{"id": "OG000", "title": "Sitagliptin", "description": "Sitagliptin 100 mg, oral, once daily for 30 weeks"}, {"id": "OG001", "title": "Placebo", "description": "Placebo to sitagliptin, 100 mg, oral, once daily for 30 weeks"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "373"}, {"groupId": "OG001", "value": "370"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "15.3"}, {"groupId": "OG001", "value": "10.0"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "nonInferiorityType": "SUPERIORITY", "pValue": "= 0.030", "statisticalMethod": "Miettinen and Nurminen", "paramType": "Between Group Difference in Percentages", "paramValue": "5.3", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "0.5", "ciUpperLimit": "10.1"}]}]}, "adverseEventsModule": {"frequencyThreshold": "5", "timeFrame": "Up to 32 weeks", "description": "The analysis population consisted all randomized participants who received at least one dose of study treatment. Events of hypoglycemia of any type were collected as efficacy endpoints in this study. AEs of symptomatic hypoglycemia could also be reported by investigators.", "eventGroups": [{"id": "EG000", "title": "Sitagliptin", "description": "Sitagliptin 100 mg, oral, once daily for 30 weeks", "deathsNumAffected": 0, "deathsNumAtRisk": 373, "seriousNumAffected": 14, "seriousNumAtRisk": 373, "otherNumAffected": 79, "otherNumAtRisk": 373}, {"id": "EG001", "title": "Placebo", "description": "Placebo to sitagliptin, 100 mg, oral, once daily for 30 weeks", "deathsNumAffected": 2, "deathsNumAtRisk": 370, "seriousNumAffected": 18, "seriousNumAtRisk": 370, "otherNumAffected": 72, "otherNumAtRisk": 370}], "seriousEvents": [{"term": "Acute myocardial infarction", "organSystem": "Cardiac disorders", "sourceVocabulary": "MedDRA 20.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 373}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 370}]}, {"term": "Atrial fibrillation", "organSystem": "Cardiac disorders", "sourceVocabulary": "MedDRA 20.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 373}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 370}]}, {"term": "Coronary artery disease", "organSystem": "Cardiac disorders", "sourceVocabulary": "MedDRA 20.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 373}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 370}]}, {"term": "Myocardial infarction", "organSystem": "Cardiac disorders", "sourceVocabulary": "MedDRA 20.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 373}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 370}]}, {"term": "Phimosis", "organSystem": "Congenital, familial and genetic disorders", "sourceVocabulary": "MedDRA 20.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 373}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 370}]}, {"term": "Colitis", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA 20.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 373}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 370}]}, {"term": "Strangulated umbilical hernia", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA 20.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 373}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 370}]}, {"term": "Cholecystitis acute", "organSystem": "Hepatobiliary disorders", "sourceVocabulary": "MedDRA 20.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 373}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 370}]}, {"term": "Bronchitis", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 20.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 373}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 370}]}, {"term": "Gastroenteritis", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 20.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 373}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 370}]}, {"term": "Groin abscess", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 20.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 373}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 370}]}, {"term": "Pyelonephritis", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 20.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 373}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 370}]}, {"term": "Sialoadenitis", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 20.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 373}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 370}]}, {"term": "Tracheitis", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 20.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 373}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 370}]}, {"term": "Urinary tract infection", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 20.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 373}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 370}]}, {"term": "Fibula fracture", "organSystem": "Injury, poisoning and procedural complications", "sourceVocabulary": "MedDRA 20.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 373}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 370}]}, {"term": "Ligament rupture", "organSystem": "Injury, poisoning and procedural complications", "sourceVocabulary": "MedDRA 20.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 373}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 370}]}, {"term": "Heart rate irregular", "organSystem": "Investigations", "sourceVocabulary": "MedDRA 20.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 373}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 370}]}, {"term": "Hyponatraemia", "organSystem": "Metabolism and nutrition disorders", "sourceVocabulary": "MedDRA 20.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 373}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 370}]}, {"term": "Endometrial adenocarcinoma", "organSystem": "Neoplasms benign, malignant and unspecified (incl cysts and polyps)", "sourceVocabulary": "MedDRA 20.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 373}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 370}]}, {"term": "Gastrointestinal tract adenoma", "organSystem": "Neoplasms benign, malignant and unspecified (incl cysts and polyps)", "sourceVocabulary": "MedDRA 20.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 373}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 370}]}, {"term": "Non-Hodgkin's lymphoma", "organSystem": "Neoplasms benign, malignant and unspecified (incl cysts and polyps)", "sourceVocabulary": "MedDRA 20.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 373}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 370}]}, {"term": "Prostate cancer", "organSystem": "Neoplasms benign, malignant and unspecified (incl cysts and polyps)", "sourceVocabulary": "MedDRA 20.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 373}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 370}]}, {"term": "Carotid artery stenosis", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA 20.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 373}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 370}]}, {"term": "Cerebral ischaemia", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA 20.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 373}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 370}]}, {"term": "Cerebrovascular accident", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA 20.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 373}, {"groupId": "EG001", "numEvents": 2, "numAffected": 2, "numAtRisk": 370}]}, {"term": "Ischaemic stroke", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA 20.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 373}, {"groupId": "EG001", "numEvents": 2, "numAffected": 2, "numAtRisk": 370}]}, {"term": "Lumbar radiculopathy", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA 20.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 373}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 370}]}, {"term": "Neuralgia", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA 20.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 373}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 370}]}, {"term": "Sciatica", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA 20.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 373}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 370}]}, {"term": "Acute respiratory failure", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA 20.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 373}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 370}]}, {"term": "Diabetic foot", "organSystem": "Skin and subcutaneous tissue disorders", "sourceVocabulary": "MedDRA 20.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 373}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 370}]}], "otherEvents": [{"term": "Nasopharyngitis", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 20.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 30, "numAffected": 24, "numAtRisk": 373}, {"groupId": "EG001", "numEvents": 35, "numAffected": 32, "numAtRisk": 370}]}, {"term": "Hypoglycaemia", "organSystem": "Metabolism and nutrition disorders", "sourceVocabulary": "MedDRA 20.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 96, "numAffected": 35, "numAtRisk": 373}, {"groupId": "EG001", "numEvents": 74, "numAffected": 24, "numAtRisk": 370}]}, {"term": "Headache", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA 20.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 36, "numAffected": 25, "numAtRisk": 373}, {"groupId": "EG001", "numEvents": 23, "numAffected": 19, "numAtRisk": 370}]}]}, "moreInfoModule": {"certainAgreement": {"piSponsorEmployee": false, "restrictionType": "OTHER", "restrictiveAgreement": true, "otherDetails": "The sponsor must have the opportunity to review all proposed abstracts, manuscripts or presentations regarding this trial 45 days prior to submission for publication/presentation. Any information identified by the sponsor as confidential must be deleted prior to submission; this confidentiality does not include efficacy and safety results. Sponsor review can be expedited to meet publication timelines."}, "pointOfContact": {"title": "Clinical Trials Disclosure", "organization": "Merck Sharp & Dohme Corp.", "email": "ClinicalTrialsDisclosure@merck.com", "phone": "1-800-672-6372"}}}, "documentSection": {"largeDocumentModule": {"largeDocs": [{"typeAbbrev": "Prot_SAP", "hasProtocol": true, "hasSap": true, "hasIcf": false, "label": "Study Protocol and Statistical Analysis Plan", "date": "2016-07-14", "uploadDate": "2019-01-18T10:19", "filename": "Prot_SAP_000.pdf", "size": 3838059}]}}, "derivedSection": {"miscInfoModule": {"versionHolder": "2024-06-24", "removedCountries": ["Argentina", "Australia", "Canada", "Czech Republic", "Czechia", "Denmark", "Estonia", "France", "Germany", "Guatemala", "Hungary", "Israel", "Korea, Republic of", "Latvia", "Mexico", "New Zealand", "Philippines", "Poland", "Puerto Rico", "Romania", "Russian Federation", "Spain", "Turkey", "United Kingdom", "United States"]}, "conditionBrowseModule": {"meshes": [{"id": "D000003920", "term": "Diabetes Mellitus"}, {"id": "D000003924", "term": "Diabetes Mellitus, Type 2"}], "ancestors": [{"id": "D000044882", "term": "Glucose Metabolism Disorders"}, {"id": "D000008659", "term": "Metabolic Diseases"}, {"id": "D000004700", "term": "Endocrine System Diseases"}], "browseLeaves": [{"id": "M7115", "name": "Diabetes Mellitus", "asFound": "Diabetes Mellitus", "relevance": "HIGH"}, {"id": "M7119", "name": "Diabetes Mellitus, Type 2", "asFound": "Type 2 Diabetes Mellitus", "relevance": "HIGH"}, {"id": "M11639", "name": "Metabolic Diseases", "relevance": "LOW"}, {"id": "M25403", "name": "Glucose Metabolism Disorders", "relevance": "LOW"}, {"id": "M7862", "name": "Endocrine System Diseases", "relevance": "LOW"}], "browseBranches": [{"abbrev": "BC18", "name": "Nutritional and Metabolic Diseases"}, {"abbrev": "BC19", "name": "Gland and Hormone Related Diseases"}, {"abbrev": "All", "name": "All Conditions"}]}, "interventionBrowseModule": {"meshes": [{"id": "D000008687", "term": "Metformin"}, {"id": "D000069036", "term": "Insulin Glargine"}, {"id": "D000068900", "term": "Sitagliptin Phosphate"}], "ancestors": [{"id": "D000007004", "term": "Hypoglycemic Agents"}, {"id": "D000045505", "term": "Physiological Effects of Drugs"}, {"id": "D000054795", "term": "Incretins"}, {"id": "D000006728", "term": "Hormones"}, {"id": "D000006730", "term": "Hormones, Hormone Substitutes, and Hormone Antagonists"}, {"id": "D000054873", "term": "Dipeptidyl-Peptidase IV Inhibitors"}, {"id": "D000011480", "term": "Protease Inhibitors"}, {"id": "D000004791", "term": "Enzyme Inhibitors"}, {"id": "D000045504", "term": "Molecular Mechanisms of Pharmacological Action"}], "browseLeaves": [{"id": "M10365", "name": "Insulin", "relevance": "LOW"}, {"id": "M11667", "name": "Metformin", "asFound": "Assessment", "relevance": "HIGH"}, {"id": "M173166", "name": "Insulin, Globin Zinc", "relevance": "LOW"}, {"id": "M347", "name": "Insulin Glargine", "asFound": "Interaction", "relevance": "HIGH"}, {"id": "M335", "name": "Sitagliptin Phosphate", "asFound": "Percutaneous", "relevance": "HIGH"}, {"id": "M10054", "name": "Hypoglycemic Agents", "relevance": "LOW"}, {"id": "M27905", "name": "Incretins", "relevance": "LOW"}, {"id": "M9789", "name": "Hormones", "relevance": "LOW"}, {"id": "M9788", "name": "Hormone Antagonists", "relevance": "LOW"}, {"id": "M27957", "name": "Dipeptidyl-Peptidase IV Inhibitors", "relevance": "LOW"}, {"id": "M19609", "name": "HIV Protease Inhibitors", "relevance": "LOW"}, {"id": "M14343", "name": "Protease Inhibitors", "relevance": "LOW"}, {"id": "M7951", "name": "Enzyme Inhibitors", "relevance": "LOW"}], "browseBranches": [{"abbrev": "Hypo", "name": "Hypoglycemic Agents"}, {"abbrev": "All", "name": "All Drugs and Chemicals"}, {"abbrev": "Infe", "name": "Anti-Infective Agents"}]}}, "hasResults": true}